OPKO Biologics Ltd., a subsidiary of OPKO Health Inc., is a clinical-stage company developing next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs, utilizing CTP and reversible PEGylation technologies.
Somatrogon – Our human growth hormone (hGH) therapy utilizes proprietary carboxyl-terminal peptide (CTP) technology to extend the therapeutic life of hGH, allowing once weekly injections as opposed to daily injections using current treatments. We’ve recently completed phase 3 clinical trials evaluating Somatrogon© as a treatment for growth hormone deficiency in both children and adults. An additional phase 3 clinical trial evaluating Somatrogon© as a treatment for pediatric growth hormone deficiency in Japan is on-going. Pfizer, Inc is our commercial partner for this product.
MOD-15014 (GLP-2) A long acting glucagon-like peptide-2 (GLP-2) analog. In pre-clinical studies it has been shown to be potent and rapid acting in the treatment of short bowel syndrome (SBS), a malabsorption disorder due to a non-functional small intestine. MOD-1501 is currently in pre-clinical development.
MOD-12014 (CTP-GHR Antagonist) Human growth hormone receptor (GHR) antagonists are used to treat acromegaly, a disorder caused by excess human growth hormone. MOD-12014 utilizes our Carboxyl Terminal Peptide (CTP) technology, which is also used in successful phase 3 product somatrogon (hGH-CTP), to extend the half life of the GHR antagonist.
MOD-1301 (CTP-IGF-1) Severe primary insulin-like growth factor 1 (IGF-1) deficiency (SPIGFD) results in short stature and increased insulin sensitivity in afflicted patients. We are developing MOD-1301, utilizing our Carboxyl Terminal Peptide (CTP) technology, as an extended release IGF-1 repletion therapy for the treatment of SPIGFD.